Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00059644 · ClinicalTrials.gov registry record · Phase 3
Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease
A Phase 3 study, sponsored by Tanabe Pharma Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 560
- Enrollment target
NCT00059644 is a Phase 3 study that was terminated before completion, run by Tanabe Pharma Corporation. The registered enrollment target is 560 participants.
The verdict
NCT00059644, a Phase 3 study, was terminated before completion, sponsored by Tanabe Pharma Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 560 participants
- Enrollment target
Study Summary
Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia (CLI), which is the most severe form of peripheral arterial disease (PAD). This trial is designed to assess the efficacy and safety of the drug in the treatment of CLI.
Interventions
- DRUG Ecraprost in lipid emulsion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2001-07 |
| Est. Completion | 2004-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00059644
The ClinicalTrials.gov registry entry for NCT00059644 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 560 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tanabe Pharma Corporation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ecraprost in lipid emulsion is the first listed.
NCT00059644 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00059644 about?
NCT00059644 is a clinical study titled "Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease". Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia (CLI), which is the most severe form of peripheral arterial disease (PAD). This trial is designed to assess the efficacy and safety of the drug in the treatment of CLI.
What is the current status of trial NCT00059644?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 560 participants. The study started on 2001-07. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00059644?
The interventions under investigation include: Ecraprost in lipid emulsion (DRUG).
Who is sponsoring clinical trial NCT00059644?
This trial is sponsored by Tanabe Pharma Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.